The push to keep up with COVID-19 variants could be the inflection point that turns genomic sequencing from a sophisticated technique into a widely accessible tool, with companies in the driver...

Apart from a few outliers, the biotech ecosystem in Germany has largely been devoid of life for over a decade. But COVID-19 has brought several more German stories into the limelight, and with them some...

BGI Genomics Co. Ltd. (SZSE:300676) raised RMB2 billion ($309 million) through the sale of 13.8 million shares at RMB145 in a private placement. Huatai Securities Co. Ltd. purchased 8.3 million shares; also buying shares were China...

Argenx is leveraging strong investor interest in mid-cap biotechs to launch a pipeline with a global footprint, built around its autoimmune candidate efgartigimod, and is lining up two additional...

With early efficacy signals emerging from a dose-finding study, Cyteir will use its new $80 million series C crossover round to gain Phase II data in multiple cancers for its DNA damage repair (DDR) molecule...

While FDA has made it clear that efficiency is a priority in adapting authorized COVID-19 products to new viral variants, questions remain about what circumstances would require a new vaccine launch, the...

As the market for real-world evidence continues to grow, Syapse plans to expand its network and improve its services with a $68 million growth equity round led by Ally Bridge. Northpoint Ventures and existing investors...

Companies developing mAbs against COVID-19 are moving to subcutaneous injection to ameliorate deployment problems that have plagued their uptake.  FDA has authorized REGEN-COV (casirivimab/imdevimab) from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bamlanivimab from Eli Lilly and Co. (NYSE:LLY) and...

FDA Commissioner Stephen Hahn Friday disclosed that he has briefed President-elect Joe Biden’s transition team. Speaking to reporters at a briefing organized by the Alliance for Health Policy, Hahn also said FDA has commissioned an...

CBC Group believes the maturing market for innovative products in Greater China represents an opportunity sufficient to support its launch of R-Bridge, the first discrete fund dedicated to non-dilutive investments in royalty streams and credit...